Pharma New Astellas, Seattle Genetics Padcev combo data spark $5.8B sales hopes

Astellas and Seattle Genetics impressed Wall Street last fall when their combination of Padcev and Merck’s Keytruda fought off advanced bladder cancer in previously untreated patients. Friday, the partners presented updated results that look even better.